Glenmark: Risk-reward turning favourable even as stocks hit 52-week low
Businesses in other geographies can drive growth, US challenges remain01-03-2018
01-03-2018
Glenmark Pharmaceuticals launches hair growth formula
Glenmark Pharmaceuticals has launched Nourkrin Woman, a clinically-proven proteoglycan replacement formula, for normalising hair growth cycle, the company has said.The product will be exclu28-02-2018
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HSBC Global Asset Management (Hong Kong) Ltd28-02-2018
Glenmark ties up with S. Korea's SCD for ophthalmic products
Glenmark Pharmaceuticals has entered into an exclusive agreement with South Korea's Sam Chun Dang Pharm Co Ltd (SCD) to develop, manufacture and market a portfolio of ophthalmic products in the US22-02-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals, South Korea, for Ophthalmic Solution Products22-02-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals, South Korea, for Ophthalmic Solution Products22-02-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting19-02-2018
Glenmark Pharma shares plunge nearly 10 per cent after Rs 104 crore loss in Q3
On Thursday, Glenmark Pharmaceuticals reported Rs 104.7 crore loss in December quarter on sharp decline in US sales. The company had reported a net profit of Rs 477.10 crore in the corresponding quarter of the previous year.09-02-2018
Financial Result For December 31, 2017
Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2017. The said meeting of the Board commenced at 10.30 a.m. and concluded at 03.30 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith....08-02-2018
Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Friday, February 9, 2018 at 08:30 a.m. - 09:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.01-02-2018